Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera (NTRA) reported insider transactions by its President, Clinical Diagnostics. The reporting person sold 1,008 shares of common stock at $192.324 on 10/27/2025 and 1,198 shares at $191.4619 on 10/28/2025. These sales were made to satisfy tax withholding and remittance obligations related to RSU vesting and were executed pursuant to a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Following the transactions, beneficial ownership was 116,259 shares after the first sale and 115,061 shares after the second sale, held directly.
Natera, Inc. (NTRA): Form 4 insider transaction
The company’s President and Chief Business Officer reported open-market sales tied to RSU tax withholding under a Rule 10b5-1(c) plan. On 10/27/2025, 781 shares of common stock were sold at $192.324. On 10/28/2025, 928 shares were sold at $191.4619. Following these transactions, the reporting person directly owned 150,699 shares.
Natera (NTRA) reported insider activity by its Chief Financial Officer. On 10/22/2025, the CFO sold 920 shares at $186.68 and converted 1,250 Restricted Stock Units (RSUs) into common stock. Additional sales included 495 shares at $187.16 on 10/23/2025 (to satisfy tax withholding on RSU vesting) and 755 shares at $196.77 on 10/24/2025. Following these transactions, the officer directly owned 69,189 shares. The sales on 10/22 and 10/24 were made under a Rule 10b5-1 plan adopted on June 14, 2024.
Natera, Inc. (NTRA) insider transaction: A reporting person who serves as Executive Chairman and Director sold 10,000 shares of Natera common stock on 10/20/2025 at a price of $190 per share, coded as an open-market sale (S). The trade was executed under a Rule 10b5-1 trading plan adopted on June 13, 2025.
Following the transaction, the reporting person beneficially owned 2,320,852 shares directly and 5,000 shares indirectly through a spouse.
Natera, Inc. (NTRA) — Form 4 insider activity: Co‑founder and director reported RSU vesting and a related tax sale. On 10/20/2025, 190 Restricted Stock Units were converted to common stock (code M). On 10/21/2025, 93 shares were sold at $187.95 (code S) to satisfy tax withholding, pursuant to a Rule 10b5‑1(c) instruction. Following these transactions, the reporting person beneficially owned 236,302 shares directly. In addition, 28,032 shares are held indirectly by Caraluna 1 Trust and 28,032 shares by Caraluna 2 Trust.
Natera (NTRA) reported an insider equity change by its SEC. and Chief Legal Officer. On 10/20/2025, 856 shares of common stock were acquired through the vesting of RSUs, and on 10/21/2025, 464 shares were sold at $187.95 to cover tax withholding and remittance obligations pursuant to a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Following these transactions, the officer directly owned 203,692 shares. Each RSU represents a right to receive one share. The RSUs vest over four years: 25% vested on January 20, 2023, with the remainder vesting in 12 equal quarterly installments thereafter.
Natera (NTRA) reported an insider transaction on a Form 4. An officer serving as President, Clinical Diagnostics sold 292 shares of common stock at $187.95 on 10/21/2025. The filing states the sale was made to satisfy tax withholding obligations related to RSU vesting and was conducted under a written instruction intended to meet the affirmative defense conditions of Rule 10b5-1(c).
Following the transaction, the officer beneficially owned 117,267 shares, held directly.
Natera, Inc. (NTRA) disclosed a Form 4 for its President and Chief Business Officer reporting a sale of 339 shares of common stock on 10/21/2025 at $187.95 per share (code S). The filing states the shares were sold to satisfy tax withholding and remittance obligations tied to vesting RSUs and were made pursuant to a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Following the transaction, the officer directly owned 152,408 shares.
Natera (NTRA) reported an insider transaction by its CEO and President, who is also a director. On 10/20/2025, 3,386 Restricted Stock Units vested and were converted to common stock (code M). On 10/21/2025, 1,603 shares were sold at $187.95 per share (code S) to satisfy tax withholding, under a Rule 10b5-1(c) instruction tied to a January 28, 2022 grant. Following these transactions, the reporting person directly beneficially owns 155,855 shares.
The RSU award vests over four years: 25% on January 20, 2023, with the remainder in 12 equal quarterly installments thereafter.
Natera (NTRA) reported an insider transaction by its chief financial officer. On Oct 20, 2025, 1,522 RSUs vested and were settled into common stock. On Oct 21, 2025, 602 shares were sold at $187.95 to satisfy tax withholding, pursuant to a written instruction intended to meet Rule 10b5-1(c) conditions. Following these transactions, the officer held 70,109 shares directly.
The RSUs relate to a grant dated Jan 28, 2022 and vest over four years: 25% vested on Jan 20, 2023, with the balance vesting in 12 equal quarterly installments thereafter.